Cellectis Reports Publication Of A Scientific Article In Nature Communications, Unveiling Non-viral Gene Therapy Approach For Sickle Cell Disease
Portfolio Pulse from Benzinga Newsdesk
Cellectis has published a scientific article in Nature Communications, revealing a non-viral gene therapy approach for treating Sickle Cell Disease.
June 12, 2024 | 8:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cellectis has published a scientific article in Nature Communications, unveiling a non-viral gene therapy approach for Sickle Cell Disease. This development could position Cellectis as a leader in gene therapy, potentially boosting investor confidence and stock prices.
The publication in a prestigious journal like Nature Communications highlights the scientific validity and potential impact of Cellectis' non-viral gene therapy approach. This could lead to increased investor interest and a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100